Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
745.77 ^USD	-0.11%		-1.85%	-3.38%

11/03	Regeneron Pharmaceuticals, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-11-2026 10:40 AM
11/03	Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $890 From $885, Maintains Buy Rating	MT

Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe

Published on 06/17/2025 at 04:01 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Regeneron Pharmaceuticals, Inc.

11/03	Regeneron Pharmaceuticals, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-11-2026 10:40 AM
11/03	Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $890 From $885, Maintains Buy Rating	MT
10/03	Regeneron Pharmaceuticals, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 09:00 AM
09/03	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study	RE
09/03	Olatorepatide obesity treatment licensed by Regeneron demonstrates positive phase 3 results in Chinese patients	RE
04/03	Regeneron Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-04-2026 09:10 AM
02/03	RBC Raises Price Target on Regeneron Pharmaceuticals to $765 From $745, Keeps Sector Perform Rating	MT
27/02	European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises	MT
27/02	Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years	CI
27/02	Regeneron, Sanofi's Dupixent Recommended for EU Approval to Treat CSU in Children	MT
27/02	Regeneron, Sanofi Get CHMP Backing for Dupixent in Younger Children With CSU	DJ
27/02	Sanofi, Regeneron Win EU Panel's Positive Opinion for Skin Disease Treatment in Young Children	MT
27/02	Ema's CHMP recommended granting a marketing authorisation for Mcombriax	RE
24/02	Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis	CI
24/02	Sanofi and Regeneron's Dupixent Approve in US as First and Only Medicine for Allergic Fungal Rhinosinusitis	CI

Ms. Anne E. Wojcicki is an Independent Director at Ajax I, a Chief Executive Officer & Director at 23andMe Holding Co. and a Chief Executive Officer & Director at 23andMe, Inc. She is on the Board of Directors at Ajax I, 23andMe Holding Co., 23andMe, Inc., Blok24, Inc., Breakthrough Prize In Life Sciences, Capri Listco, Foundation for the National Institutes of Health, Inc., Kaiser Permanente Bernard J. Tyson School of Medicine and Zipline International, Inc. She received her undergraduate degree from Yale University.

View full profile

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

REGN: Dynamic Chart

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.

Employees

15,410

Sector

Pharmaceuticals

More about the company